JP7314173B2 - 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 - Google Patents

認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 Download PDF

Info

Publication number
JP7314173B2
JP7314173B2 JP2020560750A JP2020560750A JP7314173B2 JP 7314173 B2 JP7314173 B2 JP 7314173B2 JP 2020560750 A JP2020560750 A JP 2020560750A JP 2020560750 A JP2020560750 A JP 2020560750A JP 7314173 B2 JP7314173 B2 JP 7314173B2
Authority
JP
Japan
Prior art keywords
cognitive impairment
compound
formula
sgc
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522291A (ja
JPWO2019211081A5 (https=
JP2021522291A5 (https=
Inventor
ペーター・サントナー
ヨス・プリカールツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2021522291A publication Critical patent/JP2021522291A/ja
Publication of JPWO2019211081A5 publication Critical patent/JPWO2019211081A5/ja
Publication of JP2021522291A5 publication Critical patent/JP2021522291A5/ja
Priority to JP2023113932A priority Critical patent/JP2023130467A/ja
Application granted granted Critical
Publication of JP7314173B2 publication Critical patent/JP7314173B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020560750A 2018-04-30 2019-04-12 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 Active JP7314173B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023113932A JP2023130467A (ja) 2018-04-30 2023-07-11 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18170049.3 2018-04-30
EP18170049 2018-04-30
PCT/EP2019/059390 WO2019211081A1 (en) 2018-04-30 2019-04-12 The use of sgc activators and sgc stimulators for the treatment of cognitive impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023113932A Division JP2023130467A (ja) 2018-04-30 2023-07-11 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用

Publications (4)

Publication Number Publication Date
JP2021522291A JP2021522291A (ja) 2021-08-30
JPWO2019211081A5 JPWO2019211081A5 (https=) 2022-04-04
JP2021522291A5 JP2021522291A5 (https=) 2022-04-04
JP7314173B2 true JP7314173B2 (ja) 2023-07-25

Family

ID=62091739

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560750A Active JP7314173B2 (ja) 2018-04-30 2019-04-12 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
JP2023113932A Pending JP2023130467A (ja) 2018-04-30 2023-07-11 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023113932A Pending JP2023130467A (ja) 2018-04-30 2023-07-11 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用

Country Status (6)

Country Link
US (1) US20210052528A1 (https=)
EP (1) EP3787610A1 (https=)
JP (2) JP7314173B2 (https=)
CN (1) CN112055584A (https=)
CA (1) CA3098475A1 (https=)
WO (1) WO2019211081A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10918639B2 (en) 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2020245342A1 (en) * 2019-06-07 2020-12-10 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
JP7458683B2 (ja) * 2020-12-10 2024-04-01 バイエル・アクチエンゲゼルシヤフト 眼科疾患の治療のためのｓＧＣ活性化剤の使用
TW202308634A (zh) * 2021-04-20 2023-03-01 美商賽克瑞恩醫療公司 使用sGC刺激劑之CNS疾病治療
US20240317696A1 (en) * 2021-05-14 2024-09-26 Medshine Discovery Inc. Alkyl carboxylic acid compounds and application thereof
EP4233851A1 (en) * 2022-02-25 2023-08-30 Charité - Universitätsmedizin Berlin A soluble guanylat cyclase activator for treating chronic vascular dysfunction
WO2023148203A1 (en) * 2022-02-01 2023-08-10 Charité - Universitätsmedizin Berlin A soluble guanylat cyclase activator for treating chronic vascular dysfunction
EP4543454A1 (en) * 2022-06-24 2025-04-30 Aribio Co., Ltd Compositions and methods for preventing and treating neurodegenerative diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014522383A (ja) 2011-04-13 2014-09-04 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 分枝状３−フェニルプロピオン酸誘導体およびそれらの使用
WO2017013010A1 (de) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
WO2018045276A1 (en) 2016-09-02 2018-03-08 Ironwood Pharmaceuticals, Inc. Fused bicyclic sgc stimulators

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10109859A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige Aminodicarbonsäurederivate
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102007015034A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
KR20100059952A (ko) 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
PE20091258A1 (es) 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
DE102008018675A1 (de) 2008-04-14 2009-10-15 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
TW201028152A (en) 2009-01-20 2010-08-01 Merck & Co Inc Soluble guanylate cyclase activators
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
CN101670106A (zh) 2009-09-22 2010-03-17 吉林大学 可溶性鸟苷酸环化酶的天然激活剂
US9260424B2 (en) 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
DE102009046115A1 (de) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2637659B1 (en) 2010-11-09 2016-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012076466A2 (de) 2010-12-07 2012-06-14 Bayer Pharma Aktiengesellschaft Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
CA2836202A1 (en) 2011-05-30 2012-12-06 Astellas Pharma Inc. Imidazopyridine compounds
JP5826393B2 (ja) 2011-08-12 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
US9290440B2 (en) 2012-04-16 2016-03-22 Toa Eiyo Ltd. Bicyclic compound
DE102012208530A1 (de) 2012-05-22 2013-11-28 Bayer Pharma AG Substituierte Piperidinoacetamide und ihre Verwendung
ES2603262T3 (es) 2012-07-20 2017-02-24 Bayer Pharma Aktiengesellschaft Ácidos aminoindano-carboxílicos y aminotetralin-carboxílicos sustituidos y su uso
KR102137517B1 (ko) 2012-07-20 2020-07-24 바이엘 파마 악티엔게젤샤프트 신규 5-아미노테트라히드로퀴놀린-2-카르복실산 및 그의 용도
ES2748798T3 (es) 2012-09-07 2020-03-18 Boehringer Ingelheim Int Alcoxi pirazoles como activadores de la guanilato ciclasa soluble
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CA2891976C (en) 2012-11-30 2020-07-21 Astellas Pharma Inc. Imidazopyridine compounds
SI2970243T1 (sl) 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
JP2016530292A (ja) 2013-09-05 2016-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
WO2015056663A1 (ja) 2013-10-15 2015-04-23 トーアエイヨー株式会社 ４－アミノメチル安息香酸誘導体
JP2016540017A (ja) 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
EP3172202B1 (en) 2014-07-22 2020-01-29 Boehringer Ingelheim International GmbH Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EA033697B1 (ru) 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
EP3303342B1 (en) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
JP2018537488A (ja) 2015-12-18 2018-12-20 ノバルティス アーゲー インダン誘導体、ならびに可溶性グアニル酸シクラーゼ活性化剤としてのその使用
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
US10918639B2 (en) * 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014522383A (ja) 2011-04-13 2014-09-04 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 分枝状３−フェニルプロピオン酸誘導体およびそれらの使用
WO2017013010A1 (de) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
WO2018045276A1 (en) 2016-09-02 2018-03-08 Ironwood Pharmaceuticals, Inc. Fused bicyclic sgc stimulators

Also Published As

Publication number Publication date
CA3098475A1 (en) 2019-11-07
CN112055584A (zh) 2020-12-08
EP3787610A1 (en) 2021-03-10
JP2021522291A (ja) 2021-08-30
US20210052528A1 (en) 2021-02-25
JP2023130467A (ja) 2023-09-20
WO2019211081A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
JP7314173B2 (ja) 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
US11672800B2 (en) Combination therapies with EHMT2 inhibitors
US11684621B2 (en) Combination containing sGC stimulators and mineralocorticoid receptor antagonists
RU2565034C2 (ru) Идентификация мутации lkb1 в качестве прогностического биомаркера чувствительности к ингибиторам tor-киназы
US12528819B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12427131B2 (en) Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof
TWI839690B (zh) 治療黑色素瘤的藥物組合的用途
US9358236B2 (en) Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
CA2866872A1 (en) Treatment of cancer with tor kinase inhibitors
CA2867348A1 (en) Treatment of cancer with tor kinase inhibitors
CA2528710C (en) A method of treating an anxiety disorder
HK1243645A1 (zh) 单独和与pde5抑制剂组合的sgc刺激剂、sgc活化剂用於治疗伴随系统性硬化症(ssc)的指溃疡(du)的用途
JP2025539944A (ja) 骨髄増殖性新生物を処置する方法
CN118510516A (zh) 用于治疗套细胞淋巴瘤的包含阿贝西利和pi3k和/或mtor抑制剂的药物组合
WO2025179032A1 (en) Methods of treating myelofibrosis
AU2015201138B2 (en) Treatment of cancer with TOR kinase inhibitors
JP2003063988A (ja) Ｐｄｅ阻害剤を有効成分として含有する脊髄小脳変性症治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220323

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230712

R150 Certificate of patent or registration of utility model

Ref document number: 7314173

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150